Genmab A/S (OTCMKTS:GNMSF – Get Free Report) is projected to issue its results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $3.49 per share and revenue of $1.20 billion for the quarter.
Genmab A/S Price Performance
Shares of Genmab A/S stock opened at $563.82 on Tuesday. The firm has a market capitalization of $34.71 billion, a PE ratio of 41.52 and a beta of 0.75. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12 month low of $232.34 and a 12 month high of $581.00. The business’s 50-day moving average price is $374.80 and its 200-day moving average price is $306.19.
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Featured Stories
- Five stocks we like better than Genmab A/S
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
